Search

Displaying results 3631 - 3640 of 10000 in total
  1. Drug

    Cholestyramine

    go.drugbank.com/drugs/DB01432
    ApprovedInvestigational

    Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. … Cholestyramine resin is quite hydrophilic, but insoluble in water.

    Products: VASOSAN S BTL, VASOSAN S DOSE
  2. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    at the site from which the graft is taken. … intact dermal elements for which surgical intervention is clinically indicated (also known as deep partial-thickness burns).

  3. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label]. … Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and artemisinin derivatives became available.

  4. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties.

  5. Drug

    Kanamycin

    go.drugbank.com/drugs/DB01172
    ApprovedInvestigationalVet approvedWithdrawn

    Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. … Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Trimetazidine

    go.drugbank.com/drugs/DB09069
    ApprovedInvestigational

    [A7688,L33020] However, evidence for this mechanism is controversial.[A233215] Trimetazidine is not FDA approved. However, it has been approved in France since 1978.[L33020] … [L33015] Trimetazidine has been studied as a treatment for angina pectoris since the late 1960s.

  7. Drug

    Fosaprepitant

    go.drugbank.com/drugs/DB06717
    ApprovedInvestigational

    Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant.

  8. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. … On September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.

  9. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. … Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose.

  10. Target

    Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial

    go.drugbank.com/bio_entities/BE0002254
    TargetHumans

    Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q) (PubMed

    Synonyms: Iron-sulfur subunit of complex II